Ente ea COVID-19 e fumaneha neng? Motho a ka phekoloa joang khahlanong le Coronavirus? Na ho na le moriana khahlano le coronavirus? Tsena ke lipotso tse tsebahalang haholo eseng ho coronavirus ea Patlo ea Google feela.

Ho ea ka rasaense, avaccine khahlanong le coronavirus e lokela ho lebelloa ho nka likhoeli tse 12 ho isa ho tse 18, ha borasaense ba bang ba re litlhare li kanna tsa fumaneha kapele haholo, bo-rasaense ba re

Le ha vaksine e khahlano le koronavirus e ncha e lebelletsoe ho nka nako e fetang selemo ho e etsa le ho e hlahloba, mekhoa e meng ea kalafo bakeng sa ts'okelo e bolaeang e kanna ea ba likhoeli tse 'maloa feela, litsebi tsa bophelo bo botle li re.

Batho ba fetang 417,721 ba fumanoe ba e-na le COVID-19 mme ba fetang 18,605 ba hlokahetse. Linaha tse 'maloa li koaletsoe ha palo ea ba tšoaelitsoeng ke lefu le tšoaetsanoang haholo e ntse e eketseha ka potlako.

Bo-rasaense lefats'eng ka bophara ba matha ho nts'etsapele kalafo le liente, tse tla tlameha ho etsoa liteko le liteko tsa bongaka pele li fetisetsa tlhahiso ea bongata.

"Meento e fetang 20 e nts'etsopele lefats'eng ka bophara, 'me litlhare tse' maloa li litekong tsa bongaka," 'muelli oa Mokhatlo oa Lefatše oa Bophelo o bolelletse The Media Line. "Ha ho na kalafo le vaksine e seng e ntse e le teng empa bafuputsi lefats'eng ka bophara ba e sebeletsa ka thata."

Le ha vaksine e kanna ea nka pakeng tsa likhoeli tse 12 le 18 ho netefatsoa hore e bolokehile ebile e sebetsa hantle mme e hlahisoe bakeng sa ts'ebeliso ea bongata, kalafo tse ling tse sebetsang li ka hlaha kapele haholo.

Moprofesa Peter Jay Hotez, ngaka ea likokoana-hloko e hlaheletseng ebile e le mookameli oa Sekolo sa Naha sa Baylor College of Medicine sa Tropical Medicine e Houston, Texas, o bolelletse The Media Line hore kalafo ea pele e neng e ka sebetsa khahlano le COVID-19 e tla ba kalafo e hlaselang ea serum antibody , moo lithibela-mafu tsa motho ea hlaphohileng vaerase li kenngoang ho mokuli ea kulang.

Phuputsong e phatlalalitsoeng ho The Sengoloa sa maloetse a tšoaetsanoang ka 2014, bafuputsi ba bonts'itse hore na mali a kopantsoeng a mali a ka sebetsa joang ho fokotsa sekhahla sa lefu haeba a fuoa ba nang le tšoaetso e matla ea phefumoloho (SARIs) nakoana kamora hore matšoao a bona a hlahe pele.

Ho ea ka Hotez, kalafo e latelang e tlang ho hlaha kamora sena e kanna ea ba "ho hlahisa meriana e thibelang likokoana-hloko hape ka libeke kapa likhoeli tse 'maloa, ebe litlhare tse ncha tsa lik'hemik'hale nakong ea selemo, le ente ea selemo se le seng ho isa ho tse tharo."

Ho khahlisang ke hore Hotez le sehlopha sa hae sa bo-rasaense ba ne ba se ba ntse ba e-na le vaksine ea coronavirus lilemong tse fetileng, kamora ho phatloha ha 2002-2004 SARS, e ileng ea namela China mme ea qetella e bolaile batho ba fetang 770 lefats'eng ka bophara. Leha ho le joalo, ha vaksine e fihla mothating oa liteko tsa batho ka 2016, o ile a sitoa ho fumana chelete e eketsehileng mme liteko ha lia ka tsa phetheloa.

"Nakong eo re neng re e etsa, batho ba ne ba feletsoe ke thahasello ho mafu a seoa a coronavirus le mafu a seoa," Hotez o boletse, a eketsa ka hore bafuputsi joale ba ntse ba sebeletsa ho hlahisa ente ea ente ea COVID-19 hape.

Li-Coronaviruses ke sehlopha sa livaerase tse amanang le tsona tse bakang maloetse ho kenyeletsoa le a mang a sefuba, eseng feela SARS le COVID-19.

Ngaka Rivka Abulafia-Lapid, motlhatlheledi yo mogolo wa virology kwa Yunibesithing ya Jerusalem ya Jerusalem, o dumalana le Hotez gore kalafi ya antiviral e ka nna ya nna teng mo dikgweding di le thataro le ka pelenyana go feta mokento, e kgoreletsa ditiragalo dipe tse di neng di sa lebelelwa.

"Isiraele e se ntse e na le litlhare tse 11 tse fapaneng bakeng sa teko [ho bakuli ba COVID-19]… ka hona ke re ntho ea pele e tla tsoa e tla ba sethethefatsi se tla lumellanoa hangata ke boramahlale ba lefats'e le FDA [Lijo tsa Amerika le Tsamaiso ea Lithethefatsi], e lateloe ke vaksine, "Abulafia-Lapid o bolelletse The Media Line. "Ka likhoeli tse 'maloa, ba tla tsoa ba tšoere kalafo nakong e tlang kapa mohlomong le lebenkeleng la lithethefatsi."

Abulafia-Lapid, ea qetileng lilemo tse 25 a etella pele sehlopha sa lipatlisiso naheng ea Isiraele se ikemiselitseng ho etsa ente e sebetsang khahlanong le HIV le maloetse a mang a itšireletsang mafung, a re ente efe kapa efe e tla tlameha ho feta nako e telele ea liteko e kenyeletsang mekhahlelo e mengata ea liteko tsa bongaka.

Har'a lithethefatsi tsa hajoale tse nkoang e le likhetho tsa anti-coronavirus hajoale, o supa k'hamphani ea California e thehiloeng ho biotech ea liteko tsa lithibela-mafu tsa meriana e thibelang likokoana-hloko - e neng e lekoa ho batho ba nang le vaerase ea Ebola - e le semathi sa pele ho latela tshepiso. Remdesivir e se e ntse e sebelisoa litekong tse 'maloa tse amanang le coronavirus.

Semela se seholo sa meriana sa Isiraele, Teva, hajoale, se phatlalalitse bekeng e fetileng hore se tla fana ka litekanyetso tse fetang limilione tse 6 tsa lipilisi tsa hydroxychloroquine sulphate lipetleleng tsa United States bakeng sa lipatlisiso tse ling. Meriana, eo hangata e sebelisetsoang ho phekola malaria, e ntse e batlisisoa e le mokhethoa oa ho loants'a COVID-19.

Mabapi le monyetla oa kalafo ea `` convalescent antibody serum '', eo Hotez a reng e se e ka fuoa bakuli ba kulang haholo, Abulafia-Lapid o bonts'itse hore leha kalafo e joalo e ka pholosa maphelo, mathata a maholo a ntse a le teng ka ho nyolla mokhoa ona ho batho ba likete.

Leha ho le joalo, qetellong o na le "tšepo e kholo" ea hore lefats'e le likhoeli tse tšeletseng pele ho kalafo e sebetsang.

"Nakong e tlang, re tla tlameha ho tsoa selemo se seng le se seng ka ente e ncha ea [COVID-19] hobane e fetoha joalo ka ntaramane," ho boletse Abulafia-Lapid, mme a eketsa ka hore hobane vaerase e ncha, sesole sa 'mele sa motho ha se na ts'ireletso khahlano le eona. "O hlile o hloka ho ruta 'mele [mokhoa oa ho itšireletsa khahlanong le ona]," o boletse joalo.

mohloli o moholo: Ea Medialine

SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:

Peter Jay Hotez, a prominent virologist and the dean of the Baylor College of Medicine's National School of Tropical Medicine in Houston, Texas, told The Media Line that the earliest treatment that could work against COVID-19 would be a convalescent serum antibody therapy, in which the antibodies of a person who has recovered from the virus are injected into a sick patient.
“Israel already has 11 different drugs for trial [on COVID-19 patients] … so I would say that the first thing to come out will be a drug that will be commonly agreed upon by the world's scientists and the FDA [the US Food and Drug Administration], followed by a vaccine,” Abulafia-Lapid told The Media Line.
According to Hotez, the next treatment to emerge after this will most likely be “repurposed existing antiviral drugs in a few weeks or months, then new chemical drugs within a year, and a vaccine in one to three years.